Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Hemispherx to Host Conference Call on Recent Presentation at the 2002 DART Conference and Other Recent Developments
Hemispherx Files New US Patent Application on Immune-Based Alternative Treatment to HIV/AIDS
HEMISPHERX BIOPHARMA COMPLETES FULL ENROLLMENT OF ITS PHASE III CLINICAL TRIAL FOR CHRONIC FATIGUE SYNDROME (CFS)
Hemispherx Biopharma Invited to Present New Anti HIV Data at DART Conference: Phase IIB Clinical Trials of Strategic Treatment Intervention
Hemispherx Biopharma, Inc. Adopts Stockholder Rights Plan
Hemispherx Biopharma and Sigma-Aldrich Enter Agreement to Produce Hemispherx's RNA-based Ampligen® in U.S.
Hemispherx Announces Third Quarter Results
Hemispherx Biopharma RNA Drug Technology Targets New Molecular Defects Uncovered in Prostate Cancer
HEMISPHERX BIOPHARMA PROFILED ON TOP10MICROCAPSTOCKS.COM
HEMISPHERX BIOPHARMA RNA DRUG TECHNOLOGY PIPELINE SHOWS THERAPEUTIC PROMISE IN U.S. GOVERNMENT SPONSORED RESEARCH
74
75
76
77
78
79
80
81
82
83
<<
<
>
>>
Privacy